The overall changes in the cholesterol panel with 10 mg of rosuvastatin and atorvastatin in the STARSHIP trial are shown in the current slide.

After 6 weeks of therapy, LDL-C was reduced by 45% with rosuvastatin 10 mg compared to 36% with atorvastatin 10 mg (P<.0001).  Similarly, non-HDL-C was reduced to a significantly greater extent with rosuvastatin 10 mg compared to atorvastatin 10 mg (41 % versus 33 %; P<.0001).1

No differences in HDL-C and TG levels were observed with rosuvastatin 10 mg compared to atorvastatin 10 mg.1

Reference:

1. Lloret, R et al.  Comparison of rosuvastatin versus atorvastatin in Hispanic-American patients with hypercholesterolemia (from the STARSHIP trial). American Journal of Cardiology. 2006;98:768-773.